Hakan GÜRKAN, Hakkı Onur KIRKIZLAR, Ufuk DEMİRCİ, Selma DEMİR, Elif G. ÜMİT, Sedanur Karaman GÜLARSLAN, Volkan BAŞ, Ahmet Muzaffer DEMİR, Mehmet BAYSAL

Genetic Diagnosis of Hereditary Hemorrhagic Telangiectasia: Four Novel Pathogenic Variations in Turkish Patients

Aims: Hereditary hemorrhagic telangiectasia is an autosomaldominant disorder characterized by telangiectasia, epistaxis, andvascular malformations. Pathogenic mutations were found in ENG,AVCRL1, SMAD4, and GDF genes. In this study, we present ourdatabase of patients with hereditary hemorrhagic telangiectasiaregarding the phenotype-genotype relations and discuss two novelENG gene pathogenic variations in two unrelated families.Methods: Next Generation Sequencing analysis was performed onthe peripheral blood of nine patients with hereditary hemorrhagictelangiectasia in four unrelated families. All patients were diagnosedwith hereditary hemorrhagic telangiectasia according to the Curaçaocriteria. Data on treatment and screenings of visceral involvementwere recorded from files.Results: We have found a pathogenic variation in either the ENG orACVRL1 gene in each family. Two novel pathogenic variations in theENG gene, including NM_000118.3 (ENG): c.416delC (p.P139fs*24)and NM_000118.3(ENG): c.1139dupT (p.Leu380PhefsTer16),were found in the same family. The NM_000020.2(ACVRL1):c.1298C>T (p.Pro433Leu) pathogenic variation in the ACVRL1gene in our first family and a novel heterozygous likely pathogenicNM_000020.2(ACVRL1): c.95T>C (p.Val32Ala) variation wasfound in our second family. Seven of the nine patients were treatedwith thalidomide for controlling bleeding episodes. All patientsresponded to thalidomide. In one patient, the response to thalidomidewas lost and switched to bevacizumab.Conclusion: In hereditary hemorrhagic telangiectasia, certain types ofmutations correlate with disease phenotypes and with next generationsequencing methods. New pathogenic variations can be revealed,which might help manage patients with hereditary hemorrhagictelangiectasia

PDF

___

1. Begbie ME, Wallace GMF, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003;79:18-24.
2. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-OslerWeber syndrome). Am J Med Genet 2000;91:66-7.
3. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24:203-19.
4. Bayrak-Toydemir P, Mao R, Lewin S, McDonald J. Hereditary hemorrhagic telangiectasia: An overview of diagnosis and management in the molecular era for clinicians. Genet Med 2004;6:175-91.
5. Olivieri C, Pagella F, Semino L, Lanzarini L, Valacca C, Pilotto A, et al. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J Hum Genet 2007;52:820-9.
6. Gallione C, Aylsworth AS, Beis J, Berk T, Bernhardt B, Clark RD, et al. Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 2010;152:333-9.
7. Karlsson T, Cherif H. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital. Ups J Med Sci 2018;123:153-7.
8. McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet 2015;6:1.
9. Ruiz-Llorente L, Gallardo-Vara E, Rossi E, Smadja DM, Botella LM, Bernabeu C. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 2017;21:933-47.
10. Bossler AD, Richards J, George C, Godmilow L, Ganguly A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006;27:667-75.
11. Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005;116:8-16.
12. Lesca G, Burnichon N, Raux G, Tosi M, Pinson S, Marion MJ, et al. Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat 2006;27:598.
13. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010;120:838-43.
14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
15. National Cancer Institute Common Terminology Criteri v5.0 (CTCAE). September 27, 2017. (http://ctep.cancer.gov.
16. Li S, Wang SJ, Zhao YQ. Clinical features and treatment of hereditary hemorrhagic telangiectasia. Medicine (Baltimore) 2018;97:11687.
17. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 2004;23:4018-28.
18. Park S, DiMaio TA, Liu W, Wang S, Sorenson CM, Sheibani N. Endoglin regulates the activation and quiescence of endothelium by participating in canonical and noncanonical TGF-β signaling pathways. J Cell Sci. 2013;126:1392-405.
19. Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige J-J, Bailly S, et al. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet 2014;24:1142-54.
20. Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: Mutations and manifestations. Am J Med Genet A 2006;140:463-70.
21. Sabbà C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007;5:1149-57.
22. Letteboer TG, Mager HJ, Snijder RJ, Lindhout D, Ploos van Amstel HK, Zanen P, et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008;146:2733-9.
23. Hereditary Hemorrhagic Telangiectasia Mutation Database. Salt Lake City, UT: University of Utah Department of Pathology http://www. arup.utah.edu/database/ HHT. Accessed 26 May 2019.
24. Xu M, Hou Y, Sheng L, Peng J. Therapeutic effects of thalidomide in hematologic disorders: a review. Front Med 2013;7:290-300.
25. Garg N, Khunger M, Gupta A, Kumar N. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med 2014;5:191-206.
26. Geisthoff UW, Nguyen HL, Roth A, Seyfert U. How to manage patients with hereditary haemorrhagic telangiectasia. Br J Haematol 2015;171:443-52.